Stakeholders Still Confused About Breakthrough Standards, Difference From Fast Track
Agency officials responded to almost 50 queries during a webinar on a draft guidance intended to clarify use of the fast track, breakthrough therapy, priority review and accelerated approval regulatory pathways. Most questions related to the breakthrough program.
You may also be interested in...
Letter being circulated by Rep. Bilirakis states the agency’s draft expedited approval guidance does not provide clarity for rare disease sponsors to use accelerated approval.
FDA’s much-anticipated guidance on expedited programs for drug development fills in some blanks on the new breakthrough designation, but simply advising sponsors they will need to pick up the pace on manufacturing plans and development of companion diagnostics leaves aspiring applicants wanting more, stakeholders said at DIA.
The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.